Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. PTC
5. MSFT
6. META
7. AMD
8. GMAB
9. AMZN
10. ATH

Go back to Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance

Amgen Reports Second Quarter 2021 Financial Results

August 3, 2021 4:01 PM EDT

THOUSAND OAKS, Calif., Aug. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2021. Key results include:

Total revenues increased 5% to $6.5 billion in comparison to the second quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia® (denosumab), Repatha® (evolocumab) and our biosimilar products MVASI® (bevacizumab-awwb) and KANJINTI® (trastuzumab-anns).GAAP earnings per share (EPS) decreased 73% to $0.81 driven by... More